Status:
COMPLETED
Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
Ruhr University of Bochum
Collaborating Sponsors:
Heart and Diabetes Center North-Rhine Westfalia
Solvay Pharmaceuticals
Conditions:
Atherosclerosis
Type 2 Diabetes Mellitus
Eligibility:
All Genders
35-70 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to determine whether a 6-week treatment with 4 g Omacor/day improves the baseline and postprandial endothelial function (after a high-fat meal) in patients with type 2 diab...
Detailed Description
Patients with type 2 diabetes mellitus (T2DM) have a 2 to 5-fold increase in cardiovascular mortality compared to non-diabetics. Endothelial dysfunction (ED) is an early messenger of atherosclerosis ...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
Exclusion
- History of myocardial infarction, stroke
- Severe diabetes complications
- Severe hypo- or hypertension
- Chronic alcohol abuse
- Renal failure
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2008
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00328536
Start Date
April 1 2007
End Date
November 1 2008
Last Update
May 8 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart- and Diabetes Centre NRW, Diabetes Clinic
Bad Oeynhausen, North Rhine-Westphalia, Germany, 32545